George Trainor received a B.S. degree in Chemistry from Stevens Institute of Technology in 1974. He pursued graduate studies under Prof. Yoshito Kishi at Harvard University and received M.S and Ph.D. degrees in Chemistry in 1979. Following postdoctoral studies under Prof. Ronald Breslow at Columbia University, he joined the Central Research and Development Department of the DuPont Company in 1981. After working on the chemistry of metals and carbohydrates, he initiated a project which led to the discovery and commercialization of fluorescence-tagged chain terminators for use in automated DNA sequencing. In 1991, he moved into the newly formed DuPont Merck Pharmaceutical Company working on nucleic acid-based therapeutics. After heading up the cancer therapeutic area in 1993, he moved into medicinal chemistry working in several therapeutic areas as a Senior Director under Paul Anderson. From 2002 through 2010, he worked at the Bristol-Myers Squibb Company in Lawrenceville, New Jersey as Vice President – Oncology Chemistry and Early Discovery Chemistry, leading a team of 115 chemists. His teams advanced over 30 compounds into pharmaceutical development. In 2011 he received the Heroes of Chemistry Award from the American Chemical Society for his early work of fluorescence-tagged DNA sequencing.Specialties: Pharmaceutical Discovery and Early Development, Medicinal Chemistry, Oncology Drug Discovery, Kinases